Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
10.18
-0.22 (-2.12%)
Feb 17, 2026, 3:41 PM EST - Market open
Trevi Therapeutics Employees
Trevi Therapeutics had 34 employees as of September 30, 2025. The number of employees increased by 7 or 25.93% compared to the same quarter last year.
Employees
34
Change
7
Growth
25.93%
Revenue / Employee
n/a
Profits / Employee
-$1,348,765
Market Cap
1.31B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 34 | 7 | 25.93% |
| Jun 30, 2025 | 33 | 7 | 26.92% |
| Mar 31, 2025 | 31 | 6 | 24.00% |
| Dec 31, 2024 | 26 | 1 | 4.00% |
| Sep 30, 2024 | 27 | 2 | 8.00% |
| Jun 30, 2024 | 26 | -4 | -13.33% |
| Mar 31, 2024 | 25 | 3 | 13.64% |
| Dec 31, 2023 | 25 | 0 | - |
| Sep 30, 2023 | 25 | 2 | 8.70% |
| Jun 30, 2023 | 30 | 7 | 30.43% |
| Mar 31, 2023 | 22 | -1 | -4.35% |
| Dec 31, 2022 | 25 | 1 | 4.17% |
| Sep 30, 2022 | 23 | -3 | -11.54% |
| Jun 30, 2022 | 23 | 0 | - |
| Mar 31, 2022 | 23 | 0 | - |
| Dec 31, 2021 | 24 | 2 | 9.09% |
| Sep 30, 2021 | 26 | 4 | 18.18% |
| Jun 30, 2021 | 23 | 4 | 21.05% |
| Mar 31, 2021 | 23 | 4 | 21.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 952 |
| Immatics | 645 |
| Intellia Therapeutics | 403 |
| uniQure | 209 |
| Monte Rosa Therapeutics | 147 |
| Kodiak Sciences | 123 |
| DBV Technologies | 117 |
| Savara | 59 |
TRVI News
- 26 days ago - Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA) - PRNewsWire
- 5 weeks ago - Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference - PRNewsWire
- 2 months ago - Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer - PRNewsWire
- 2 months ago - Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond - Seeking Alpha
- 3 months ago - Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates - PRNewsWire
- 3 months ago - Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025 - PRNewsWire
- 3 months ago - Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference - PRNewsWire